EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis

Frank M Balis, Elizabeth Rieger, Nancy J Bunin, JoAnn Gardiner, Leslie M Shaw, Timothy S Olson, Michael C Milone

Cancer Chemotherapy and Pharmacology · 2025-12 · 95 (1)

DOI: 10.1007/s00280-025-04757-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 11.02.2025. Verfasst von Frank M Balis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Children's Hospital of Philadelphia and University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA. …. Hauptthemen laut MEDLINE: Busulfan, Models, Biological, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alex's Lemonade Stand Foundation for Childhood Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Apply population pharmacokinetic modeling to a single institution busulfan therapeutic drug monitoring (TDM) data set from infants and children to refine dosing methods.

Methods

One-compartment pharmacokinetic model was fit to busulfan TDM data from 328 infants and children with malignant and non-malignant diseases treated with busulfan-containing transplant conditioning regimens. Age-dependence of busulfan clearance scaled to body weight and body surface area (BSA) was compared, and busulfan AUC was simulated for a BSA-scaled dose of 100 mg/m 2 combined with a BSA-banded dosing table for infants and children with a BSA < 0.5 m 2 .

Results

Busulfan clearance scaled to body weight is age-dependent. Clearance in children ≤ 3 years (0.234 L/[h•kg]) is higher than the typical value for the population, (0.205 L/[h•kg]), and 48% of children < 5 years have subtherapeutic busulfan AUCs after the first dose. Busulfan clearance scaled to BSA (typical value, 5.47 L/[h•m 2 ]) is more uniform across the pediatric age span, except for infants (≤ 1 year, 4.27 L/[h•m 2 ]). Simulated busulfan AUCs with a dose of 100 mg/m 2 for patients with a BSA ≥ 0.5 m 2 combined with a BSA-banded dosing table for patients with a BSA < 0.5 m 2 achieved a therapeutic AUC after the first dose in 49% more patients than body weight scaled doses.

Conclusion

Our model predicts a greater proportion of children would achieve a therapeutic busulfan AUC after the first dose with a dose of 100 mg/m 2 /d combined with the infant dosing table for patients with a BSA < 0.5 m 2 compared to body weight-scaled dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BusulfanModels, BiologicalAntineoplastic Agents, AlkylatingHumansInfantChild, PreschoolChildMaleDrug MonitoringFemaleBody Surface AreaArea Under CurveBody WeightAdolescentTransplantation ConditioningDose-Response Relationship, DrugAge Factors

Stichwörter der Autor:innen

Body surface areaBody weightBusulfanDosing tableStem cell transplantationTherapeutic drug monitoring

Substanzen

BusulfanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Division of Oncology, Children's Hospital of Philadelphia and University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA. balisf@CHOP.edu.
  • Children's Hospital of Philadelphia, 3401 Civic Center Blvd, CTRB4024, Philadelphia, PA, 19104, USA. balisf@CHOP.edu.
  • Division of Oncology, Children's Hospital of Philadelphia and University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.
  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 19104, USA.

Förderung

  • Alex's Lemonade Stand Foundation for Childhood Cancer

Zitieren

APA

Balis, F. M., Rieger, E., Bunin, N. J., Gardiner, J., Shaw, L. M., Olson, T. S., & Milone, M. C. (2025). New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-025-04757-w

Vancouver

Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, et al. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology. 2025;95(1). doi:10.1007/s00280-025-04757-w

BibTeX
@article{Balis2025,
  author = {Balis, Frank M and Rieger, Elizabeth and Bunin, Nancy J and Gardiner, JoAnn and Shaw, Leslie M and Olson, Timothy S and Milone, Michael C},
  title = {New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  volume = {95},
  number = {1},
  doi = {10.1007/s00280-025-04757-w}
}
Kostenlos starten →